Heilongjiang ZBD Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

De CEO Heilongjiang ZBD Pharmaceutical is Jiujiang Yan, benoemd in Jul2022, heeft een ambtstermijn van 2.33 jaar. bezit rechtstreeks 0.016% van de aandelen van het bedrijf, ter waarde CN¥ 1.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 5.3 jaar.

Belangrijke informatie

Jiujiang Yan

Algemeen directeur

CN¥1.2m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.3yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

CEO

Jiujiang Yan (46 yo)

2.3yrs

Tenure

CN¥1,170,500

Compensatie

Mr. Jiujiang Yan serves as Director of Heilongjiang ZBD Pharmaceutical Co., Ltd. since October 2019 and erves as its General Manager since July 2022 and served as its Deputy General Manager since August 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jiujiang Yan	GM & Director	2.3yrs	CN¥1.17m	0.016% CN¥ 1.8m
Lei Wang	CFO & Accounting Supervisor	5.2yrs	CN¥694.20k	0.016% CN¥ 1.8m
Zhongfang Zhang	Board Secretary	1.6yrs	CN¥290.50k	0.011% CN¥ 1.2m
Tianzhu Li	Deputy General Manager	2.5yrs	CN¥452.40k	0.011% CN¥ 1.2m
Xiuzhen Li	Deputy General Manager	1.5yrs	CN¥204.20k	0.011% CN¥ 1.2m

2.3yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 603567 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jiujiang Yan	GM & Director	5.1yrs	CN¥1.17m	0.016% CN¥ 1.8m
Tong Hua Fang	Chairman of the Board	13.7yrs	CN¥2.69m	geen gegevens
Pei Bao Lan	Chairman of the Supervisory Board	10.7yrs	geen gegevens	geen gegevens
Xue Dong Li	Supervisor	13.7yrs	geen gegevens	0.000060% CN¥ 6.5k
Ruichao Lin	Independent Director	3.5yrs	CN¥80.00k	geen gegevens
Gongda Hou	Independent Director	1.5yrs	CN¥49.20k	geen gegevens
Yunqi Zhang	Director	5.5yrs	CN¥80.00k	geen gegevens
Jing Huang	Employee Supervisor	1.8yrs	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 603567 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Heilongjiang ZBD Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Heilongjiang ZBD Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.005 (vs CN¥0.14 in 3Q 2023)

Investor sentiment improves as stock rises 25%

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.096 in 2Q 2023)

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Heilongjiang ZBD Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.27 in 1Q 2023)

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 15%

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.091 loss in 3Q 2022)

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.096 (vs CN¥0.086 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 24, 2023

First quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.17 in 1Q 2022)

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.091 loss per share (vs CN¥0.04 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.086 (vs CN¥0.14 in 2Q 2021)

Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) announces an Equity Buyback for CNY 50 million worth of its shares.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) announces an Equity Buyback for CNY 50 million worth of its shares.

First quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.18 in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.066 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.068 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.51 (vs CN¥0.48 in FY 2019)

New 90-day high: CN¥11.89

New 90-day low: CN¥11.11

New 90-day low: CN¥11.54

New 90-day low: CN¥12.11

Third quarter earnings released

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

Heilongjiang ZBD Pharmaceutical Co., Ltd. announced that it expects to receive CNY 2.0810905 billion in funding

First half earnings released

New 90-day high - CN¥13.50

Heilongjiang ZBD Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 12, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd